18591-70-3 Usage
General Description
6-METHYL[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-8-OL is a chemical compound with the molecular formula C7H6N4O. It is a heterocyclic compound containing a triazolo-pyridazinol ring. 6-METHYL[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-8-OL is a member of the triazolo-pyridazine class of chemicals, and it contains a methyl group at the 6 position. It has potential applications in medicinal chemistry and pharmaceutical research due to its unique structure and potential biological activity. Further research is needed to fully understand the properties and potential uses of 6-METHYL[1,2,4]TRIAZOLO[4,3-B]PYRIDAZIN-8-OL.
Check Digit Verification of cas no
The CAS Registry Mumber 18591-70-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,5,9 and 1 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 18591-70:
(7*1)+(6*8)+(5*5)+(4*9)+(3*1)+(2*7)+(1*0)=133
133 % 10 = 3
So 18591-70-3 is a valid CAS Registry Number.
InChI:InChI=1/C6H6N4O/c1-4-2-5(11)6-8-7-3-10(6)9-4/h2-3,11H,1H3
18591-70-3Relevant articles and documents
Preparation and application of triazole heterocyclic compound containing heteroaryl amide structure
-
Paragraph 0121-0124, (2019/11/14)
The invention discloses a triazole heterocyclic compound containing a heteroaryl amide structure, a geometrical isomer of triazole heterocyclic compound containing the heteroaryl amide structure and pharmacologically acceptable salt, hydrate, solvate or p
Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against plasmodium falciparum dihydroorotate dehydrogenase
Marwaha, Alka,White, John,El-mazouni, Farah,Creason, Sharon A,Kokkonda, Sreekanth,Buckner, Frederick S.,Charman, Susan A.,Phillips, Margaret A.,Rathod, Pradipsinh K.
, p. 7425 - 7436 (2012/11/07)
Plasmodium falciparum causes approximately 1 million deaths annually. However, increasing resistance imposes a continuous threat to existing drug therapies. We previously reported a number of potent and selective triazolopyrimidine-based inhibitors of P.
